Видео ютуба по тегу Dlbcl

DLBCL in 2023: Top Docs Discuss the LATEST in Diffuse Large B-Cell Lymphoma | Treatments & Research
DLBCL in 2023: Top Docs Discuss the LATEST in Diffuse Large B-Cell Lymphoma | Treatments & Research
Understanding Diffuse Large B-Cell Lymphoma (DLBCL)
Understanding Diffuse Large B-Cell Lymphoma (DLBCL)
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
The current state of treatment for limited-stage DLBCL
The current state of treatment for limited-stage DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL) - Aggressive B-Cell Neoplasm - Non-Hodgkin’s Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) - Aggressive B-Cell Neoplasm - Non-Hodgkin’s Lymphoma
Prognostic Factors in DLBCL
Prognostic Factors in DLBCL
Current treatment options for older patients with DLBCL
Current treatment options for older patients with DLBCL
Double-hit DLBCL
Double-hit DLBCL
Dr. Dunleavy Discusses ABC DLBCL Research
Dr. Dunleavy Discusses ABC DLBCL Research
Treatment Options for Diffuse Large B-Cell Lymphoma (DLBCL)
Treatment Options for Diffuse Large B-Cell Lymphoma (DLBCL)
The role of molecular subtyping in DLBCL and implications for treatment decisions
The role of molecular subtyping in DLBCL and implications for treatment decisions
Managing early & late relapse after first-line therapy for DLBCL
Managing early & late relapse after first-line therapy for DLBCL
Understanding Diffuse Large B-cell Lymphoma (DLBCL) and Its Subtypes
Understanding Diffuse Large B-cell Lymphoma (DLBCL) and Its Subtypes
Advice for DLBCL Patients
Advice for DLBCL Patients
How to treat Diffuse Large B-Cell Lymphoma (DLBCL) - Dr. Carla Casulo
How to treat Diffuse Large B-Cell Lymphoma (DLBCL) - Dr. Carla Casulo
Using PET to predict failure to salvage therapy in patients with DLBCL
Using PET to predict failure to salvage therapy in patients with DLBCL
How Does Your DLBCL Subtype Impact Your Treatment Options?
How Does Your DLBCL Subtype Impact Your Treatment Options?
Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents
Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents
Impaired immunity in DLBCL survivors
Impaired immunity in DLBCL survivors